In a case series [54] of three patients with HIV infection affected by Merkel-cell carcinoma, pembrolizumab administration seemed not to modify viro-immunological status, with all patients having an HIV viral load consistently undetectable at baseline and after treatment, maintaining stable CD4+ T cell counts during treatment with ICI. Here, CD4 is linked to HIV infectious disease.